Navigation Links
Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA)
Date:3/15/2012

BERLIN, March 15, 2012 /PRNewswire/ -- InterMune, Inc. (NADSAQ: ITMN) today reported that Germany's Federal Joint Committee (G-BA) has announced its decision granting the additional benefit of Esbriet® (pirfenidone) in adults for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  Esbriet's additional benefit was classified as stage 4 (not quantifiable benefit)  in the rating system established under Germany's AMNOG pharmaceutical law.  A non-quantifiable benefit means that the drug has an additional benefit, which will be defined in the future via experience in daily clinical use or clinical studies.  Based on this, a stage of 1-3 will be assigned.  G-BA is the highest decision-making body of the self-governing healthcare system in Germany.

Today's final assessment of Esbriet's added benefit by the G-BA is improved from the preliminary assessment of the benefits of Esbriet issued by the Institute for Quality and Efficiency in Healthcare (IQWiG) in December 2011.  In its preliminary assessment, IQWiG did not determine an additional benefit of Esbriet.

"We are pleased that the G-BA has recognized the additional benefit of Esbriet for patients with IPF," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "Esbriet is the first orphan drug to be evaluated under the new German system for assessing the additional benefit to patients of a new medicine.  As the only therapy approved for IPF, G-BA determined that there is no appropriate comparator treatment to Esbriet.  Today's decision applies to all adult patients with mild-to-moderate IPF and ensures continued reimbursement in Germany for the first drug shown to be efficacious, safe and generally well-tolerated in this relentless and uniformly fatal disease."

Dr. Markus Leyck Dieken, InterMune's Senior Vice President and Country Manager for Germany, said, "We appreciate the input of those who help
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
2. New Data Demonstrate Longer-Term Safety Profile of Esbriet®
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
5. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
6. New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
7. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
8. Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program
9. Sleep Breathing Machine Shows Clear Benefits in Children with Sleep Apnea
10. Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
11. Recent Study Reveals Benefits to Women From DHEA Hormone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
(Date:5/21/2015)... , May 21, 2015 ... has announced the addition of the ... (Ankle Replacement, Digit Replacement, Elbow Replacement, Hip ... to 2019" report to their offering. ... knee replacement was valued at $4,470.9 million ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 ... has announced the addition of the "North ... & Graft), by Application (Surgical Wound, & Ulcer), ... Forecast to 2019" report to their offering. ... wound care market is estimated to grow at ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... , GENEVA, Switzerland, December 14 ... Meeting was held,in Bermuda on 7th December. In excess of ... and overwhelmingly approved all the resolutions,put forward. , ... Shortt of Galmoy,as the new Director of Corporate Communications. In ...
... , , STUART, ... LBMH) is pleased to announce the addition of Mr. Joseph Farish ... Farish is s graduate of the University of Florida (Bachelor of ... has been a member of the Florida Bar for more than ...
Cached Medicine Technology:Calcitech Holds Annual General Meeting 2Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 2Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 3Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 4
(Date:5/22/2015)... 2015 Memorial Day weekend is typically considered ... is offering some tips to help promote safe travel. , ... be 383 traffic fatalities this Memorial Day weekend. Amica is ... Traffic Safety Association: , , Always ... wearing a seatbelt, whether they’re driving or riding along as ...
(Date:5/22/2015)... Philadelphia, PA (PRWEB) May 22, 2015 According ... as a hub for drug related death, totaling almost 2,500 ... number, as reported by state officials, totals 2,489 deaths stemming ... numbers work out, Pennsylvania loses seven people every day to ... Philadelphia has been singled out as one of the most ...
(Date:5/22/2015)... 22, 2015 A Phase 3 ... American Society of Clinical Oncology (ASCO)’s annual meeting ... rates for those patients who received bevacizumab in ... pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is an antibody ... is already routinely used to treat many other ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... of Multifamily Housing, Marc Zuluaga, has been selected by ... innovative engineering. The award winners are featured in the ... given to 40 building industry professionals age 40 and ... to the building community, as well as in other ...
(Date:5/22/2015)... Puritan Medical Products, a Maine ... diagnostic, environmental, and forensics industries celebrates 96 years ... the US. At a time when countless manufacturing ... Puritan remains committed to designing and manufacturing their ... facility. , Since 1919, Puritan has focused on ...
Breaking Medicine News(10 mins):Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2
... L. Myers ... Kids, WASHINGTON, Jan. 24 The following statement,was issued ... A new global survey released by the U.S. Centers for ... and even higher,rates of exposure to secondhand smoke, among children ...
... Reproductive Science Center to Open Melrose, Massachusetts Location in ... ... Science Center,of New England announces the opening of a new office in ... and Malden. The,Melrose office, located at 830 Main Street, Suite 207, will ...
... Inc.,(Nasdaq: OMCL ), a leading provider of system solutions to ... discuss,the company,s fourth quarter financial results., What: ... When: January 31, 2008, 3:00 p.m. PST ... Rob ...
... inflammation-induced colon cancer in its tracks , Individuals ... increased risk of developing colon cancer. New data generated ... identified a central role for the soluble factor TNF-alpha ... which inflammation of the bowel was induced by administration ...
... life span of mice with inherited Lou Gehrig,s disease ... that nearly doubles the life span of mice with ... University of Iowa researchers, who made the finding after ... , The study results, published online Jan. 24 in ...
... RMD ),announced today that on Thursday, February 7, ... of fiscal year 2008, ended December 31,2007. ResMed will ... and will host a conference call to review its ... call is scheduled to begin at 1:30 p.m. Pacific ...
Cached Medicine News:Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 2Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 3Health News:Leading IVF Practice to Open 11th New England Location 2Health News:Omnicell Schedules Fourth Quarter Earnings Call 2Health News:JCI table of contents: Jan. 24, 2008 2Health News:JCI table of contents: Jan. 24, 2008 3Health News:JCI table of contents: Jan. 24, 2008 4Health News:JCI table of contents: Jan. 24, 2008 5Health News:JCI table of contents: Jan. 24, 2008 6Health News:JCI table of contents: Jan. 24, 2008 7Health News:Surprise in Lab Helps ID Drug to Fight ALS 2Health News:RESMED to Webcast Second Quarter 2008 Earnings Conference Call 2
... superb field flatness, high UV transmission ... extra long working distances, these objectives ... with inverted microscopes. Because of their ... ELWD DM,objectives can be used universally ...
Inquire...
... Axiovert 40 inverted microscope ... have ever expected from a microscope in this ... quality, and functionality. Axiovert 40 has been designed ... as possible thus increasing the efficiency of ...
... is an advanced inverted microscope ... exclusive CFI60 optical system yields ... aperatures and longer working distances. ... to take full advantage of ...
Medicine Products: